Coagulase-negative staphylococci: Difference between revisions
From IDWiki
Content deleted Content added
m Text replacement - "[[Cellular shape::" to "[[Shape::" |
No edit summary |
||
| Line 3: | Line 3: | ||
==Organisms== |
==Organisms== |
||
*'' |
*''Staphylococcus epidermidis'' group |
||
** |
**[[Staphylococcus epidermidis]] |
||
** |
**[[Staphylococcus capitis]] |
||
** |
**[[Staphylococcus simulans]] |
||
| ⚫ | |||
*''Staphylococcus haemolyticus'' group |
*''Staphylococcus haemolyticus'' group |
||
** |
**[[Staphylococcus haemolyticus]] |
||
** |
**[[Staphylococcus hominis]] |
||
** |
**[[Staphylococcus devriesei]] |
||
* |
*[[Staphylococcus saprophyticus]]: mainly causes UTIs |
||
* |
*[[Staphylococcus massiliensis]] |
||
* |
*[[Staphylococcus lugdenensis]]: has more in common with Staphylococcus aureus and should never be considered a contaminant |
||
*Unclear grouping |
*Unclear grouping |
||
** |
**[[Staphylococcus lyticans]] |
||
** |
**[[Staphylococcus pettenkoferi]] |
||
** |
**[[Staphylococcus petrasii]] |
||
** |
**[[Staphylococcus pseudolugdunensis]] |
||
| ⚫ | |||
==Management== |
==Management== |
||
*Generally resistant to |
*Generally resistant to [[β-lactams]] |
||
*First-line: vancomycin |
*First-line: [[vancomycin]] |
||
*Alternatives: linezolid, daptomycin, |
*Alternatives: [[linezolid]], [[daptomycin]], [[co-trimoxazole]], [[ciprofloxacin]], [[doxycycline]] |
||
[[Category:Gram-positive cocci]] |
[[Category:Gram-positive cocci]] |
||
Revision as of 11:19, 21 November 2022
- Group of Gram-positive cocci that are catalase positive and coagulase negative
Organisms
- Staphylococcus epidermidis group
- Staphylococcus haemolyticus group
- Staphylococcus saprophyticus: mainly causes UTIs
- Staphylococcus massiliensis
- Staphylococcus lugdenensis: has more in common with Staphylococcus aureus and should never be considered a contaminant
- Unclear grouping
Management
- Generally resistant to β-lactams
- First-line: vancomycin
- Alternatives: linezolid, daptomycin, co-trimoxazole, ciprofloxacin, doxycycline
References
- ^ Antonio Ramos-Martínez, Patricia González-Merino, Elena Suanzes-Martín, Marta Murga-de la Fuente, Gabriela Escudero-López, Ane Andrés-Eisenhofer, Esther Expósito-Palomo, Andrea Gutierrez-Villanueva, Itziar Diego-Yagüe, Elena Múñez, Ana Fernandez-Cruz, Jorge Calderón-Parra. Risk of endocarditis among patients with coagulase-negative Staphylococcus bacteremia. Scientific Reports. 2023;13(1). doi:10.1038/s41598-023-41888-7.
- ^ Sara F. Haddad, Brian D. Lahr, Sebastian Santos Patarroyo, Supavit Chesdachai, Kami D. Kies, John C. O’Horo, Daniel C. DeSimone, Parham Sendi, Larry M. Baddour. Bloodstream Infection Due to Coagulase-Negative Staphylococci: Impact of Species on Prevalence of Infective Endocarditis. Antibiotics. 2023;12(9):1453. doi:10.3390/antibiotics12091453.
